USPTO serial 79437092
Serial No. 79437092
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- IN, SUNG HYUN
- Law office
- TMEG LAW OFFICE 103
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Deadline: 27 Jul 2026
Need help with Serial No. 79437092?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Office Action issues
The examiner has identified that you need to clarify your color claim, provide your email address, and ensure a U.S.-licensed attorney is appointed to represent you.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives for human use; anti-inflammatories for human use; antibacterial pharmaceutical preparations for human use; antibiotics for human use; antifungal preparations for human use; antivirals for human use; cardiovascular pharmaceutical preparations for human use; dermatological pharmaceutical preparations for human use; pharmaceutical preparations for human use for inhaling for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations for human use acting on the central nervous system; pharmaceutical preparations and substances for human use for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for human use, used in hematology and in tissue and organ transplantation; pharmaceutical preparations for human use for the prevention and treatment of eye diseases; pharmaceutical preparations for human use for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders related to the immune system; pharmaceutical preparations for human use for the prevention and treatment of kidney diseases; pharmaceutical preparations for human use for the prevention and treatment of diabetes; pharmaceutical preparations for human use for the prevention and treatment of hypertension; pharmaceutical preparations for human use for the prevention and treatment of skin conditions; pharmaceutical preparations for human use, used in dermatology; pharmaceutical preparations for human use, used in urology; pharmaceutical preparations for human use, used in ophthalmology; pharmaceutical preparations for human use for the prevention and treatment of cancer and tumors; pharmaceutical preparations for human use for the prevention and treatment of allergies; pharmaceutical preparations for human use for the prevention and treatment of bone diseases; pharmaceutical preparations for human use for the prevention and treatment of respiratory diseases and asthma | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 3, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 21, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 27, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 27, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 15, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 14, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 3, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 3, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 1, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 13, 2025 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |